32 related articles for article (PubMed ID: 38702822)
1. Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma.
McIntyre CA; Lawrence SA; Richards AL; Chou JF; Wong W; Capanu M; Berger MF; Donoghue MTA; Yu KH; Varghese AM; Kelsen DP; Park W; Balachandran VP; Kingham TP; D'Angelica MI; Drebin JA; Jarnagin WR; Iacobuzio-Donahue CA; Allen PJ; O'Reilly EM
Cancer; 2020 Sep; 126(17):3939-3949. PubMed ID: 32573775
[TBL] [Abstract][Full Text] [Related]
2. Landscape of
Salem ME; El-Refai SM; Sha W; Puccini A; Grothey A; George TJ; Hwang JJ; O'Neil B; Barrett AS; Kadakia KC; Musselwhite LW; Raghavan D; Van Cutsem E; Tabernero J; Tie J
JCO Precis Oncol; 2022 Mar; 6():e2100245. PubMed ID: 35319967
[TBL] [Abstract][Full Text] [Related]
3. Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer.
Fakih M; Tu H; Hsu H; Aggarwal S; Chan E; Rehn M; Chia V; Kopetz S
Oncologist; 2022 Aug; 27(8):663-674. PubMed ID: 35472176
[TBL] [Abstract][Full Text] [Related]
4. Pathogenic genomic alterations in Chinese pancreatic cancer patients and their therapeutical implications.
Zhao Z; Li X; Wang F; Xu Y; Liu S; Han Q; Yang Z; Huang W; Yin Z; Liu Q; Tan H; Ma T; Si S; Huang J; Yuan H; Li W; Liu R
Cancer Med; 2023 May; 12(10):11672-11685. PubMed ID: 36999792
[TBL] [Abstract][Full Text] [Related]
5. Large-scale clinico-genomic profile of non-small cell lung cancer with KRAS G12C: Results from LC-SCRUM-Asia study.
Tamiya Y; Matsumoto S; Zenke Y; Yoh K; Ikeda T; Shibata Y; Kato T; Nishino K; Nakamura A; Furuya N; Miyamoto S; Kuyama S; Nomura S; Ikeno T; Udagawa H; Sugiyama E; Nosaki K; Izumi H; Sakai T; Hashimoto N; Goto K
Lung Cancer; 2023 Feb; 176():103-111. PubMed ID: 36634571
[TBL] [Abstract][Full Text] [Related]
6. Precision medicine for pancreatic cancer: Characterizing the clinico-genomic landscape and outcomes of KRAS G12C-mutated disease.
Keane F; Chou JF; Walch H; Schoenfeld J; Singhal A; Cowzer D; Harrold E; O'Connor C; Park W; Varghese A; El Dika I; Balogun F; Yu KH; Capanu M; Schultz N; Yaeger R; O'Reilly EM
J Natl Cancer Inst; 2024 May; ():. PubMed ID: 38702822
[TBL] [Abstract][Full Text] [Related]
7. Targeting KRAS in PDAC: A New Way to Cure It?
He Q; Liu Z; Wang J
Cancers (Basel); 2022 Oct; 14(20):. PubMed ID: 36291766
[TBL] [Abstract][Full Text] [Related]
8. Targeting KRAS for the potential treatment of pancreatic ductal adenocarcinoma: Recent advancements provide hope (Review).
Zhang J; Darman L; Hassan MS; Von Holzen U; Awasthi N
Oncol Rep; 2023 Nov; 50(5):. PubMed ID: 37800636
[TBL] [Abstract][Full Text] [Related]
9. Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer.
Qunaj L; May MS; Neugut AI; Herzberg BO
Front Oncol; 2023; 13():1252516. PubMed ID: 37790760
[No Abstract] [Full Text] [Related]
10. Targeting KRAS
Torres-Jiménez J; Espinar JB; de Cabo HB; Berjaga MZ; Esteban-Villarrubia J; Fraile JZ; Paz-Ares L
Drugs; 2024 Apr; ():. PubMed ID: 38625662
[TBL] [Abstract][Full Text] [Related]
11. Targeting KRAS in pancreatic cancer.
Stickler S; Rath B; Hamilton G
Oncol Res; 2024; 32(5):799-805. PubMed ID: 38686056
[TBL] [Abstract][Full Text] [Related]
12. KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.
Lim TKH; Skoulidis F; Kerr KM; Ahn MJ; Kapp JR; Soares FA; Yatabe Y
Lung Cancer; 2023 Oct; 184():107293. PubMed ID: 37683526
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
